RBC Capital analyst Leonid Timashev downgraded ADC Therapeutics (NYSE: ADCT) from Outperform to Sector Perform with a price target of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE